Hoffmann-La Roche

Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older

Retrieved on: 
Thursday, October 13, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, LinkedIn, U.S. Securities and Exchange Commission, BioNTech, Hoffmann-La Roche, Pierre Geneves, Omicron, RNA transfection, Risk, SEC, Vaccination, Science, YouTube, Vaccine, Peer review, Pfizer–BioNTech COVID-19 vaccine, Research, Twitter, Publication, Program, Facebook, Cancer, EUA, Private Securities Litigation Reform Act, Infection, Emergency Use Authorization, Company, Marketing, DO, Form, Awareness, Pediatrics, Safety, Ageing, Immunotherapy, News, Clinical trial, COVID-19, Regeneron Pharmaceuticals, Pfizer, BNT162, Genentech

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Key Points: 
  • Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
  • For more than 170 years, we have worked to make a difference for all who rely on us.
  • We routinely post information that may be important to investors on our website at www.pfizer.com .
  • This press release contains forward-looking statements of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.

Inotrem Announces Positive Outcome of its Phase II ASTONISH Trial in Septic Shock Patients Demonstrating Efficacy of Nangibotide

Retrieved on: 
Thursday, October 13, 2022
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, COVID-19, Clinical Trials, Septic shock, High-dependency unit, Hoffmann-La Roche, Sepsis, Immunomodulation, PRIME, EMA, Infection, Patient, Standard of care, Organ dysfunction, Research, Mortality, Senior, Precision medicine, IIB, Efficacy, CEO, Incidence, Immunotherapy, Survival, Myocardial infarction, Death, Safety, Nangibotide, FDA, COVID-19, Pharmaceutical industry

ASTONISH was designed to show the efficacy of nangibotide in septic shock with a precision medicine approach aiming to identify patients who benefit the most from this innovative treatment.

Key Points: 
  • ASTONISH was designed to show the efficacy of nangibotide in septic shock with a precision medicine approach aiming to identify patients who benefit the most from this innovative treatment.
  • Nangibotide is the first TREM-1 inhibitor and ASTONISH confirms its potential as a new therapeutic option for the septic shock patient population.
  • In preclinical septic shock models, nangibotide was able to restore appropriate inflammatory response, vascular function, and improved animals survival post septic shock.
  • The Efficacy, Safety and Tolerability of nangibotide in Patients with Septic Shock (ASTONISH) phase IIb trial is a Randomized, Double-blind, Placebo Controlled Dose Selection Study that was performed in Europe and in the US.

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age

Retrieved on: 
Wednesday, October 12, 2022
LinkedIn, U.S. Securities and Exchange Commission, BioNTech, Hoffmann-La Roche, Pierre Geneves, Omicron, RNA transfection, Risk, SEC, Science, YouTube, EMA, Vaccine, Person, Peer review, Pfizer–BioNTech COVID-19 vaccine, Research, Twitter, Publication, Program, Facebook, Cancer, EUA, Private Securities Litigation Reform Act, Infection, Emergency Use Authorization, Company, Marketing, Form, Awareness, Pediatrics, Safety, Ageing, Immunotherapy, News, Clinical trial, COVID-19, Regeneron Pharmaceuticals, Pfizer, BNT162, Genentech

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Key Points: 
  • Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
  • For more than 170 years, we have worked to make a difference for all who rely on us.
  • In addition, to learn more, please visit us onand follow us on Twitter at @Pfizer and @Pfizer News , LinkedIn , YouTube and like us on Facebook at Facebook.com/Pfizer .
  • This press release contains forward-looking statements of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age

Retrieved on: 
Wednesday, October 12, 2022
COVID-19, Teens, Infectious Diseases, Children, Clinical Trials, Family, Biotechnology, Pharmaceutical, Consumer, Health, LinkedIn, U.S. Securities and Exchange Commission, BioNTech, Hoffmann-La Roche, Pierre Geneves, Omicron, RNA transfection, Risk, SEC, Science, YouTube, EMA, Vaccine, Person, Peer review, Pfizer–BioNTech COVID-19 vaccine, Research, Twitter, Publication, Program, Facebook, Cancer, EUA, Private Securities Litigation Reform Act, Infection, Emergency Use Authorization, Company, Marketing, Form, Awareness, Pediatrics, Safety, Ageing, Immunotherapy, News, Clinical trial, COVID-19, Regeneron Pharmaceuticals, Pfizer, BNT162, Genentech

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Key Points: 
  • Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
  • For more than 170 years, we have worked to make a difference for all who rely on us.
  • We routinely post information that may be important to investors on our website at www.pfizer.com .
  • This press release contains forward-looking statements of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.

Araris Biotech AG Appoints Filippo Mulinacci, Ph.D., MBA as Chief Business Officer

Retrieved on: 
Wednesday, October 12, 2022
Serono, Doctor of Philosophy, Therapeutic index, BIT, HSG, Hoffmann-La Roche, Pharmacy, MBA, Paul Scherrer Institute, Technology, University, Jaden Philogene-Bidace, Turin, Business development, ADC, Innovation, GLOBE, ETH Zurich, Head, University of St. Gallen, PSI, FDA, Hotel manager, Control, Fine chemical, Chemistry

AU ZH, Switzerland, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, is pleased to announce the appointment of Filippo Mulinacci, Ph.D., MBA as chief business officer.

Key Points: 
  • AU ZH, Switzerland, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, is pleased to announce the appointment of Filippo Mulinacci, Ph.D., MBA as chief business officer.
  • We are thrilled to welcome Filippo to our executive team, said Philipp Spycher, Ph.D., chief executive officer of Araris Biotech.
  • Araris stands to make an impact in the ADC space and I am honored to be a part of the company.
  • Araris Biotech AG is pioneering the development of its novel antibody-drug conjugate (ADC)-linker technology to enable efficient and precise production of ADCs.

Matinas BioPharma to Present New MAT2203 (Oral Amphotericin B) Data During IDWeek 2022

Retrieved on: 
Wednesday, October 12, 2022
RNA transfection, Adult, Pharmacist, National, Walter, Society of Infectious Diseases Pharmacists, Infectious Diseases Society of America, University of Minnesota, DNA, Solution, Epidemiology, Enactment, NYSE, MPH, Makerere University, Amphotericin B, Private Securities Litigation Reform Act, Company, LNC, Mycosis, PIDS, Cryptococcosis, GLOBE, Consultant, Hoffmann-La Roche, Amikacin, Infectious Diseases Institute, Diagnosis, Vaccine, Walter E. Washington Convention Center, Research, Gilead Sciences, Technology, BioNTech, HIV, Organic acid, IDSA, ID, Form 10-K, Washington Convention Center, Risk, Physician, Sale, Harbor–UCLA Medical Center, SEC, ABC, Patient, Infection, Partnership, Society, Abstract (summary), Forward-looking statement, Mucormycosis, Pharmaceutical industry, Bachelor of Medicine, Bachelor of Surgery, Genentech, MD

BEDMINSTER, N.J., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform delivery technology, today announced three upcoming oral data presentations during IDWeek 2022, the premier U.S. meeting of leaders in the field of infectious diseases taking place in-person at the Walter E. Washington Convention Center, in Washington DC from October 19-23, 2022.

Key Points: 
  • The data from these three presentations provide a deeper understanding of MAT2203s safety profile and impressive efficacy against two of the deadliest invasive fungal infections in cryptococcal meningitis and mucormycosis, said Theresa Matkovits, Ph.D., Chief Development Officer of Matinas BioPharma .
  • Matinas BioPharma is a biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology.
  • The Company is focused on developing an internal and external pipeline of drugs candidates based on the LNC platform.
  • Matinas BioPharmas product candidates are all in a development stage and are not available for sale or use.

Flatiron Health Expands Leadership Team with Two New Executive Hires

Retrieved on: 
Tuesday, October 11, 2022
Health Technology, Health, Oncology, People, Hoffmann-La Roche, Flatiron, Ara, Culture, Oscar Health, Policy, Health, COO, Patient, Research, Real world evidence, Real, Cancer, SVP, CPO, Creativity, Audible, Data science, Compliance, Management

Flatiron Health is pleased to announce today the appointment of two seasoned executives to the companys executive leadership team: Bruce Gottlieb, as Chief Operating Officer (COO) and Ara Tucker, as Chief People Officer (CPO).

Key Points: 
  • Flatiron Health is pleased to announce today the appointment of two seasoned executives to the companys executive leadership team: Bruce Gottlieb, as Chief Operating Officer (COO) and Ara Tucker, as Chief People Officer (CPO).
  • Bruce joins Flatiron with extensive executive experience scaling operations and driving strategic growth at healthcare companies including Zocdoc, Oscar Health, and MeiraGTx.
  • Ara , a human resources executive, attorney and published author, joins Flatiron after holding leadership roles focused on scaling the employee journey as well as transforming company culture at Cityblock Health and Audible.
  • Flatiron Health is a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients today and tomorrow.

Lineage Announces Notice of Allowance of Two Patents Covering Processes for Manufacturing Allogeneic Oligodendrocyte Progenitor and Retinal Pigmented Epithelium Cells

Retrieved on: 
Monday, October 10, 2022
Biotechnology, Genetics, Health, Clinical Trials, IND, European Patent Office, Injury, Program, SCI, Patent, EPO, Infection, Compte rendu, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, TASE, Cancer, Company, United States Patent and Trademark Office, IP, VAC2, FDA, Large-cell lung carcinoma, Hoffmann-La Roche, Intention, Degenerative disease, Lineage Cell Therapeutics, Annual report, Roche, California Institute for Regenerative Medicine, Cell, Security (finance), Priority right, U.S. Securities and Exchange Commission, USPTO, Spinal cord injury, Ageing, OPC, Disease, SEC, Spinal cord, Geographic atrophy, Patient, Orphan drug, NYSE American, Food, Â, Retinal, Disability, Forward-looking statement, Severe cognitive impairment, Auditory neuropathy, Regenerative medicine, European Patent Convention, Pharmaceutical industry, Genentech

16/750,975, entitled Dorsally-Derived Oligodendrocyte Progenitor Cells From Human Pluripotent Stem Cells, with claims covering proprietary manufacturing processes developed by Lineage for its oligodendrocyte progenitor cell therapy candidate (OPC1) for the treatment of spinal cord injury (SCI).

Key Points: 
  • 16/750,975, entitled Dorsally-Derived Oligodendrocyte Progenitor Cells From Human Pluripotent Stem Cells, with claims covering proprietary manufacturing processes developed by Lineage for its oligodendrocyte progenitor cell therapy candidate (OPC1) for the treatment of spinal cord injury (SCI).
  • These new patents highlight our ability to generate differentiated cell types from undifferentiated pluripotent cells and are valuable outputs from our platform.
  • With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials.
  • Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements.

Last Chance to Register for This Biosimilars Training Course: Covering the Regulatory Pathways and Challenges for Both the EU and US (October 11-12, 2022) - ResearchAndMarkets.com

Retrieved on: 
Friday, October 7, 2022
Health, Biotechnology, Master of Science, IFPMA, EFPIA, EMEA, University of Surrey, Patient, University, Publishing, Industry, IMI, Artificial intelligence, Marloes, Hoffmann-La Roche, University College Utrecht, Pharmaceutical medicine, List of life sciences, Pharmaceutical industry

in Pharmaceutical Medicine from the University of Surrey (UK) and has worked in the pharmaceutical industry for more than 35 years, primarily at global or European headquarters sites.

Key Points: 
  • in Pharmaceutical Medicine from the University of Surrey (UK) and has worked in the pharmaceutical industry for more than 35 years, primarily at global or European headquarters sites.
  • He has gained a wealth of experience and a comprehensive view on what information is needed to evaluate the benefit/risk ratio of drugs for patients and healthy volunteers.
  • He applies new technologies and Artificial Intelligence to facilitate the business and let people focus on what they can do best.
  • Also, she contributed to the ongoing IMI PREFER project in Europe, focused on the generation and use of patient preference data.

The Worldwide Infectious Disease In Vitro Diagnostics Industry is Expected to Reach $56.6 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, October 7, 2022
Infectious Diseases, Biotechnology, Health Technology, Health, Adoption, ICU, Technology, Prevalence, Diagnosis, Infection, Severe acute respiratory syndrome coronavirus 2, CAGR, POC, Patient, BioMérieux, HIV, Industry, Tuberculosis, Awareness, Hoffmann-La Roche, MDR, HPV, COVID-19, USD, BD, Medical device, Pharmaceutical industry, Application

The global infectious disease in vitro diagnostics market size is expected to reach USD 56.60 billion by 2030, registering a CAGR of -7.4% from 2022 to 2030, according to this report.

Key Points: 
  • The global infectious disease in vitro diagnostics market size is expected to reach USD 56.60 billion by 2030, registering a CAGR of -7.4% from 2022 to 2030, according to this report.
  • The rising prevalence of infectious diseases, such as tuberculosis & COVID-19, and technological advancements are projected to drive the product demand in the coming years.
  • The rising prevalence of multi-drug resistant infections is enhancing the early diagnosis of infectious diseases.
  • Competitive rivalry is estimated to increase during the forecast period owing to the expected launch of novel biomarker kits.